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Background. Unlike most acute viral infections controlled with the appearance of virus-specific neutralizing antibodies (NAbs),
primary HIVinfectionsare not metwith suchpotent and early antibody responses.This bringsinto questioniforhowthe presence
of potent antibodies can contribute to primary HIV control, but protective efficacies of antiviral antibodies in primary HIV
infectionshaveremainedelusive;and,ithasbeenspeculated thatevenNAbinductioncouldhaveonlyalimitedsuppressiveeffect
on primary HIV replication once infection is established. Here, in an attempt to answer this question, we examined the effect of
passive NAb immunization post-infection on primary viral replication in a macaque AIDS model. Methods and Findings. The
inoculums for passive immunization with simian immunodeficiency virus mac239 (SIVmac239)-specific neutralizing activity were
prepared by purifying polyclonal immunoglobulin G from pooled plasma of six SIVmac239-infected rhesus macaques with NAb
induction in the chronic phase. Passive immunization of rhesus macaques with the NAbs at day 7 after SIVmac239 challenge
resulted in significant reduction of set-point plasma viral loads and preservation of central memory CD4 T lymphocyte counts,
despite thelimiteddetectionperiod oftheadministered NAb responses.Peripheral lymph node dendritic cell (DC)-associated viral
RNA loads showed a remarkable peak with the NAb administration, and DCs stimulated in vitro with NAb-preincubated SIV
activated virus-specific CD4 T lymphocytes in an Fc-dependent manner, implying antibody-mediated virion uptake by DCs and
enhanced T cell priming. Conclusions. Our results present evidence indicating that potent antibody induction post-infection can
result in primary immunodeficiency virus control and suggest direct and indirect contribution of its absence to initial control
failure in HIV infections. Although difficulty in achieving requisite neutralizing titers for sterile HIV protection by prophylactic
vaccination has beensuggested, this study points out a possibility of non-sterile HIV control by prophylactic vaccine-induced, sub-
sterile titers of NAbs post-infection, providing a rationale of vaccine-based NAb induction for primary HIV control.
Citation: Yamamoto H, Kawada M, Takeda A, Igarashi H, Matano T (2007) Post-Infection Immunodeficiency Virus Control by Neutralizing
Antibodies. PLoS ONE 2(6): e540. doi:10.1371/journal.pone.0000540
INTRODUCTION
In the natural courses of HIV infections, the host immune
responses fail to contain the virus replication and allow persistent
plasma viremia. While virus-specific cytotoxic T lymphocyte
(CTL) responses exert strong suppressive pressure on primary
HIV replication [1–7], the contribution of virus-specific antibodies
in clearance of primary HIV infection has remained unclear [8].
Neutralizing antibodies (NAbs) play a central role in control of
most viral infections, but in HIV infections, NAb induction is not
efficient in the early phase due to its unusual neutralization-resistant
nature, such as the sophisticated masking of neutralizing epitopes in
HIV envelope [8–11], and protective efficacies of post-infection
NAbs in vivo have remained elusive. While evidence of virus escape
implies NAb selective pressure to a certain extent [10,12–13], it has
been speculated that post-infection NAbs could exert only a limited
suppressive effect on primary HIV replication [14–16].
Post-infection passive NAb immunization studies in macaque
AIDS models would contribute to elucidation of its protective
role, in complementation with studies determining the requisites
for sterile protection by pre-challenge administered NAb titers
[14,16–21]. A model of CCR5-tropic simian immunodeficiency
virus (SIV) infection that induces acute loss of memory CD4
+ T
cells like HIV infections in humans [22–25] would be adequate for
assessment of post-infection NAb efficacies in primary immuno-
deficiency virus infection.
In the present study, we examined the effect of passive NAb
immunization at day 7 post-challenge on primary viral replication
in a macaque AIDS model of CCR5-tropic SIVmac239 infection.
Remarkably, our analysis revealed control of primary SIVmac239
replication by the passive NAb immunization post-infection.
METHODS
Animal experiments
Burmese rhesus macaques (Macaca Mulatta) were maintained in
accordance with the Guideline for Laboratory Animals of National
Institute of Infectious Diseases and National Institute of Bio-
medical Innovation. Major histocompatibility complex class I
(MHC-I) haplotypes were determined by reference strand-
mediated conformation analysis as described previously [6,26].
Blood collection, vaccination, virus challenge, passive immuniza-
tion, and lymph node biopsy were performed under ketamine
anesthesia. For vaccination, animals intramuscularly received
a priming with 5 mg of CMV-SHIVdEN DNA encoding
SIVmac239 Gag, Pol, Vif, and Vpx, SIVmac239-HIV-1DH12
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intranasal booster six weeks later with 1610
8 CIU (cell infectious
units) of replication-competent Sendai virus expressing Gag (SeV-
Gag) in macaque V5 or 6610
9 CIU of F-deleted replication-
defective SeV-Gag in other vaccinees as described previously [6].
Animals were challenged intravenously with 1,000 TCID50 (50
percent tissue culture infective dose) of SIVmac239, three months
after booster in case of vaccinees. For passive immunization,
animals were intravenously administered with 300 mg of anti-SIV
immunoglobulin G (IgG) or control IgG at day 7 post-challenge.
Antibody preparation
Pools of plasma showing SIVmac239-specific NAb titers of 1:4 to
1:64 were obtained from six SIVmac239-infected rhesus macaques
with NAb induction in the chronic phase for preparing the IgG
inoculums for passive NAb immunization. IgG was purified from
the plasma after heat-inactivation and filtration by Protein G
Sepharose 4 Fast Flow (Amersham) and concentrated by Amicon
Ultra 4, MW50000 (Millipore) to 30 mg/ml. This IgG solution
had SIVmac239-specific NAb titer of 1:16; i.e., 5 ml of 16-fold-
diluted antibodies killed 5 ml of 10 TCID50 SIVmac239 on MT-4
cells. Control IgG was prepared from non-infected rhesus
macaques. Neutralizing F(ab’)2 was obtained by pepsin digestion
with Immunopure F(ab’)2 purification kit (Pierce).
Quantitation of plasma viral loads
Plasma RNA was extracted using High Pure Viral RNA kit
(Roche Diagnostics). Serial five-fold dilutions of RNA samples
were amplified in quadruplicate by reverse transcription and
nested PCR using SIVmac239 gag-specific primers to determine
the end point. Plasma SIV RNA levels were calculated according
to the Reed-Muench method as described previously [6]. The
lower limit of detection is approximately 4610
2 copies/ml.
Measurement of virus-specific neutralizing titers
Serial two-fold dilutions of heat-inactivated plasma or purified
antibodies were prepared in duplicate and mixed with 10 TCID50
of SIVmac239. In each mixture, 5 ml of diluted sample was
incubated with 5 ml of virus. After 45-min incubation at room
temperature, each 10-ml mixture was added into 5610
4 MT-4
cells/well in 96-well plates. Day 12 culture supernatants were
harvested and progeny virus production was examined by ELISA
for detection of SIV p27 core antigen (Beckman-Coulter) to
determine 100% neutralizing endpoint. The lower limit of titration
is 1:2.
Measurement of virus-specific T-cell responses
Virus-specific T-cell levels were measured by flow-cytometric
analysis of gamma interferon (IFN-c) induction as described
previously [6]. Peripheral blood mononuclear cells (PBMCs) were
cocultured with autologous herpesvirus papio-immortalized B
lymphoblastoid cell lines infected with a vesicular stomatitis virus
G (VSV-G)-pseudotyped SIVGP1 for SIV-specific stimulation.
The pseudotyped virus was obtained by cotransfection of COS-1
cells with a VSV-G-expression plasmid and the SIVGP1 DNA, an
env- and nef-deleted simian-human immunodeficiency virus
(SHIV) molecular clone DNA. Intracellular IFN-c staining was
performed using CytofixCytoperm kit (Becton Dickinson). Fluo-
rescein isothiocianate-conjugated anti-human CD4, Peridinin
chlorophyll protein-conjugated anti-human CD8, allophycocya-
nin-conjugated anti-human CD3, and phycoerythrin-conjugated
anti-human IFN-c antibodies (Becton Dickinson) were used.
Specific T-cell levels were calculated by subtracting non-specific
IFN-c
+ T-cell frequencies from those after SIV-specific stimula-
tion. Specific T-cell levels less than 100 cells per million PBMC are
considered negative.
Quantitation of cell-associated viral loads
Right and left inguinal lymph nodes and right and left axillary
lymph nodes were obtained from macaques by biopsy at days 7, 8,
10, and 14 post-challenge, respectively. For measurement of
dendritic cell (DC)-associated viral loads, CD1c
+ DCs were
positively selected to over 99% purity using a macaque CD1c
+ DC
magnetic sorting system (Miltenyi Biotech) from CD20
2 lym-
phocytes negatively-selected from lymph nodes. CD1c
2CD20
2
cells were used for measurement of non-DC-associated viral loads.
Cell-associated viral RNA was extracted using RNeasy kit
(Qiagen) and quantitated by LightCycler real-time PCR system
(Roche Diagnostics) using SIV gag-specific primers and probes.
The lower limit of detection is approximately 1,000 copies/10
6
cells.
Antigen presentation assay in vitro
PBMCs obtained in the chronic phase from SIVmac239-
controllers were attached to culture plates for 4 h, and adhesive
cells were cultured in the presence of 50 ng/ml GM-CSF (R&D
Systems) and 5 ng/ml IL-4 (R&D Systems) for 5 days to obtain
CD1c
+CD83
+CD86
+HLA-ABC
+HLA-DR
+ immature DCs [27].
Alternatively, CD1c
+ DCs were positively selected from CD20-
depleted PBMCs as described above. For antigen presentation
assay, 1610
5 of the in vitro-generated DCs (Exp. 1, 2, and 3) or
the positively-selected CD1c
+ DCs (Exp. 4) were pulsed for 17 h
with 2,000 TCID50 of SIVmac239 (corresponding to 2610
6 SIV
RNA copies and 3 ng of SIV p27) alone or preincubated for
45 min with 1.5 mg of either control IgG, neutralizing IgG, or
neutralizing F(ab’)2. Autologous PBMCs were cocultured with
these pulsed DCs and then subjected to measurement of specific
IFN-c induction.
Statistical analysis
Statistical analysis was performed by Prism software version 4.03
(GraphPad Software, Inc.). Set point plasma viral loads and
peripheral CD95
+CD28
+ central memory CD4
+ T-cell counts
around 3 months after challenge of the naive controls (n=7) and
NAb-immunized macaques (n=4) were log-transformed for
improvement of normality and compared by two-tailed unpaired
t test with significance levels set at p,0.05. Then their geometric
means with 95% confidence interval were calculated. Due to the
limited number of samples for each group providing difficulty for
their normality testing, the two groups were additionally compared
by nonparametric Mann-Whitney U test for confirmation of
results. No significant difference in CD95
+CD28
+ central memory
CD4
+ T-cell counts just before challenge was observed between
the two groups (p=0.68 by unpaired two-tailed t test with Welch’s
correction and p=0.31 by Mann-Whitney U test) (data not
shown).
RESULTS
SIV control by post-infection passive NAb
immunization
While most SIVmac239-infected naive macaques usually fail to
elicit NAb responses during the early phase of infection, some
acquire detectable levels of NAbs against the challenge strain in
the late phase. IgG purified from plasma pools of such
SIVmac239-infected macaques with NAb induction, showing in
SIV Control by Antibodies
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passive immunization as polyclonal anti-SIV NAbs. In the first
part of this study, naive Burmese rhesus macaques were
challenged intravenously with SIVmac239 followed by passive
immunization with 10 ml of the polyclonal NAbs (300 mg IgG) at
day 7 post-challenge (Figure 1A). Seven naive control macaques
challenged with SIVmac239, including two infused with non-SIV-
specific control antibodies, all failed to contain viral replication
with persistent viremia (Figure 1B). These macaques showed peak
plasma viral loads between days 7 and 14 post-challenge and most
had set-point viral loads exceeding 1610
4 SIV RNA copies/ml
plasma. In contrast, four rhesus macaques passively immunized at
day 7 with polyclonal NAbs showed significantly lower plasma
viral RNA loads (p=0.0033 by unpaired t test and p=0.0061 by
Mann-Whitney U test) compared with naive controls around
3 months post-challenge (Figures 1B&1C). Two of the NAb-
immunized macaques, NA1 and NA4, controlled SIV replication
with undetectable set-point plasma viremia. Thus, post-infection
passive immunization of macaques with polyclonal NAbs had
a significant suppressive effect on set-point viral replication.
Figure 1. Effect of post-challenge passive NAb immunization on primary SIV infection. (A) List of naive controls and NAb-immunized macaques.
Experiments using macaques indicated by asterisk have previously been performed [6]. (B) Plasma viral loads after SIVmac239 challenge (SIV RNA
copies/ml). Left panel, naive controls; right panel, NAb-immunized macaques shown by red lines and naive controls by gray lines for comparison. (C)
Statistical analysis of plasma viral loads around 3 months post-challenge between naive controls (n=7) and NAb-immunized macaques (n=4). The
geometric mean (indicated by the longer bar) of viral loads in naive controls is 6.5610
4 copies/ml, and its 95% confidence interval (indicated by the
shorter bars) is 1.1610
424.0610
5 copies/ml. The geometric mean in NAb-immunized macaques is 9.1610
2 copies/ml, and its 95% confidence interval
is 1.6610
225.1610
3 copies/ml. The difference between the two groups was statistically significant by unpaired two-tailed t test (p=0.0033) and by
non-parametric Mann-Whitney U test (p=0.0061). Viral loads of macaques NA1 and NA4 were calculated as the lower limit of detection shown as the
dashed line (400 copies/ml). (D) Plasma NAb responses after challenge. (+), positive; (2), negative. All detected titers were no more than 1:2.
doi:10.1371/journal.pone.0000540.g001
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Plasma NAb responses in the NAb-immunized macaques were
detected marginally at day 10 post-infection but became undetectable
within one week after the passive NAb immunization (Figure 1D),
implying that the NAbs were rapidly exhausted for virus clearance.
None elicited detectable denovo NAb responses past then. In the naive
controls, no SIVmac239-specific NAbs were detected throughout the
course. This discrepancy between the transient NAb detection and
the persistent viremia control in the NAb-immunized macaques
differed from previously-reported, dose-dependent establishment of
sterile protection from CXCR4-tropic SHIV infection by pre-
challenge passive NAb immunization [18–21].
Difference in total CD4
+ T-cell counts was not found
throughout the course between the two groups (Figure 2A).
Reductions in peripheral CD95
+ CD28
+ central memory CD4
+ T-
cell counts [28–29] were observed in the naive controls after SIV
challenge (Figure 2B). The NAb-immunized macaques, however,
showed significantly higher central memory CD4
+ T-cell counts
around 3 months post-challenge than those in the naive controls
(p=0.0066 by unpaired t test and p=0.0061 by Mann-Whitney U
test) (Figures 2B&2C), suggesting amelioration of central memory
CD4
+ T-cell loss in the early phase of SIV infection by transient
NAb responses around week 1 post-challenge. All of these NAb-
immunized macaques showed efficient virus-specific CD8
+ T-cell
induction at week 8 (Figure 3), although difference in the levels
between the two groups was not significant, implying its possible
enrollment in the observed viral control.
Post-infection passive NAb immunization in
vaccinees
Our previous trial of a DNA-prime/SeV-Gag vector-boost vaccine
in Burmese rhesus macaques has shown vaccine-based, NAb-
independent control of SIVmac239 replication, suggesting associa-
tion of MHC-I haplotype with this control [6,30]. We then
examined possible synergy of post-challenge passive NAb immuni-
zation with the prophylactic CTL-based vaccination in suppression
of SIV replication in two groups of macaques possessing MHC-I
haplotype 90-088-Ij and 90-120-Ia, respectively (Figure 4A). In the
former group of macaques possessing 90-088-Ij, vaccinees failed to
control SIV replication even after passive NAb immunization
(Figure 4B). In the latter group of macaques possessing 90-120-Ia,a l l
4 vaccinees without NAb immunization controlled SIVmac239
replication and had undetectable plasma viral loads after week 8
post-challenge(Figure4B).Allofthemrapidlyselectedforamutation
escapingfromGag206-216epitope-specificCTLbyweek5,suggesting
a strong selective pressure on the virus by this CTL [6]. As for the
Figure 2. Central memory CD4
+ T-cell counts in naive controls and
NAb-immunized macaques. (A) Peripheral CD4
+ T-cell counts (cells/ml).
(B) Peripheral CD95
+CD28
+ central memory CD4
+ T-cell counts (cells/ml)
[28]. (C) Statistical comparison of CD28
+CD95
+ central memory CD4
+ T-
cell counts around 3 months post-challenge. The geometric mean
(indicated by the longer bar) of central memory CD4
+ T-cell counts in
naive controls is 1.7610
2 counts/ml, and its 95% confidence interval
(indicated by the shorter bars) is 1.1610
222.7610
2 counts/ml. The
geometric mean in NAb-immunized macaques is 4.3610
2 counts/ml,
and its 95% confidence interval is 2.9610
226.3610
2 counts/ml. The
difference between the two groups was statistically significant by
unpaired two-tailed t test (p=0.0066) and by non-parametric Mann-
Whitney U test (p=0.0061).
doi:10.1371/journal.pone.0000540.g002
Figure 3. SIV-specific CD8
+ T-cell frequencies at week 8 post-
challenge in naive controls and NAb-immunized macaques.
doi:10.1371/journal.pone.0000540.g003
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became undetectable by week 5 and rapid selection of CTL escape
mutation was not observed (data not shown). SIV-specific CD8
+ T-
cellfrequenciesatweek2intheNAb-immunizedvaccineesVA2and
VA3 were comparable with the vaccinees without NAb immuniza-
tion, while SIV-specific CD4
+ T-cell induction at week 2 was
observed in just one (V5) of the four vaccinees without NAb but in
both of the NAb-immunized vaccinees (Figure 4C). These results
suggest, even in the NAb-immunized vaccinees, a dominant effect of
vaccine-induced cellular immune responses on control of SIV
replication, although implying a possibility of NAb-mediated
augmentation of CTL vaccine-based viral control.
Antibody-mediated virion uptake by DCs and T cell
priming
Inorder to assess the possibility ofaltered virus distribution byNAbs,
CD1c
+ DCs were isolated from peripheral lymph nodes of
unvaccinated, SIVmac239-challenged macaques before and after
passive NAb immunization, and DC-associated SIV RNA levels
were quantified at the initial stage of infection. In three naive control
macaques, accumulation of viral RNA to CD1c
+ DCs was undetect-
ableatdays7, 8, and 10post-challengebut becamedetectableatday
14 (Figure 5A). This elevation of DC-associated viral loads following
peak viremia was consistent with previous immunohistochemistry
reports on SIV and HIV-2 challenge experiments [31–32]. In
marked contrast, both of macaques NA3 and NA4 immunized with
NAbs at day 7 post-challenge showed immediate accumulation of
viral RNA in CD1c
+ DCs at day 8 (one day after NAb
immunization), suggesting antibody-mediated virion accumulation
to DCs in vivo. Cell-associated viral loads in CD1c
2CD20
2 non-
DCs were at comparable levels between the two groups, indicating
that the rapid increase in DC-associated viral loads after NAb
immunization was not due to changes in viral loads in lymph nodes.
Then an in vitro antigen presentation assay was performed to
assume whether the early viral RNA accumulation in DCs could
Figure 4. Effect of post-challenge passive NAb immunization in vaccinees. (A) List of vaccinees with or without passive immunization. (B) Plasma
viral loads after challenge (SIV RNA copies/ml). Left panel, MHC-I haplotype 90-088-Ij-positive macaques; right panel, 90-120-Ia-positive macaques.
Red lines represent NAb-immunized vaccinees. (C) SIV-specific CD4
+ T-cell and CD8
+ T-cell frequencies at week 2 post-challenge.
doi:10.1371/journal.pone.0000540.g004
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peripheral blood of macaques that controlled SIVmac239 replica-
tion were pulsed with antibody-neutralized SIV, and autologous
PBMCs were cocultured with these pulsed DCs for measurement of
specific IFN-c induction. In all four sets of experiments, efficient
IFN-c induction in CD4
+ T cells was observed after stimulation by
DCs pulsed with SIV preincubated with NAb but not byDCs pulsed
with SIV alone, SIV preincubated with control antibodies, or SIV
preincubated with Fc-depleted neutralizing F(ab’)2 (Figure 5B).
Efficient IFN-c induction in CD8
+ T cells was not observed even
after coculture with NAb-preincubated SIV-pulsed DCs except for
one (Exp. 4). Overall, augmentation of virus-specific T-cell
stimulation was observed by the coexistence of NAbs, suggesting
their involvement in antigen presentation.
DISCUSSION
The present study showed suppression of primary SIV replication
by passive NAb immunization post-infection, suggesting a possi-
bility of HIV control by potent antibody induction during the
acute phase of infection. It reversely follows that its absence may
be involved in an increase in the burden of acute infectious viral
loads and abrogation of virus-specific cellular immune responses,
leading to initial control failure in HIV infections.
While this study does not exclude possibilities of additional
antibody-mediated protective mechanisms such as antibody-
dependent cell-mediated cytotoxicity or recently-reported com-
plement virolysis [33], the non-sterile but consistent viral control at
the set point by passive NAb immunization despite only transient
detection of NAb responses during the acute phase coheres with
involvement of cellular immune responses in this control [27,34–
36]. Thus, results may provide additional interpretations to
previous NAb passive immunization studies [14,16–21], which
have mostly utilized CXCR4-tropic SHIV-challenged macaques
and shown sterile protection by high titers of pre-challenge or very
early post-challenge NAbs.
A technical confinement of this study is the use of polyclonal
antibodies which may include not only NAbs but also non-
neutralizing anti-SIV antibodies for passive immunization.
However, our finding of primary SIV control by post-infection
passive immunization with the anti-SIV inoculums with neutral-
izing activity presents significant evidence suggesting that potent
antibodies post-infection can contribute to control of primary
immunodeficiency virus infection. Whether neutralizing activity is
required for the enhanced SIV control by passive immunization
remains to be assessed in future studies. Our in vitro results suggest
a possibility of virus-specific CD4
+ T-cell activation by NAbs, and
neutralizing activity may contribute to protection of these virus-
specific CD4
+ T cells from SIV trans-infection via DCs [37–38],
possibly counteracting the abrogation of the optimal concert of
adaptive immunity between CD4
+ T and CD8
+ T cells usually
observed in the natural course of pathogenic immunodeficiency
virus infection [23,25,39]. The possibility of failure in antibody-
mediated priming of effective cellular immune responses by
preexisting vaccine-induced dominant responses may account for
lack of viral control in the NAb-immunized vaccinee possessing
MHC-I haplotype 90-088-Ij.
Despite suggested technical difficulties in achieving requisite
neutralizing titers for sterile HIV protection by prophylactic
vaccination, our results indicate a possibility of non-sterile HIV
control by secondary expansion of prophylactic vaccine-induced,
sub-sterile titers of NAbs post-infection, providing a rationale of
vaccine-based NAb induction for primary HIV control. More
understanding of the mechanism may lead to a more certain
rationale for careful induction of NAbs and CTLs by vaccination,
maybe potentially capable of synergistic HIV-1 control.
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Figure 5. Antibody-mediated SIV uptake by DCs and T cell priming.
(A) Peripheral lymph node-derived non-DC (CD1c
2CD20
2 lympho-
cytes)-associated (left panel) and CD1c
+CD20
2 DC-associated viral loads
(right panel). (B) In vitro antigen presentation assay. Either in vitro-
generated DCs (Exp. 1, Exp. 2, and Exp. 3) or positively-selected CD1c
+
DCs (Exp. 4) prepared from PBMCs were pulsed with SIV alone (SIV), SIV
preincubated with control antibodies (SIV+Control Ab), SIV preincu-
bated with NAbs (SIV+Neutralizing Ab), or SIV preincubated with Fc-
depleted NAbs (SIV+Neutralizing F[ab’]2). Autologous PBMCs were
cocultured with these pulsed DCs and then subjected to measurement
of specific IFN-c induction.
doi:10.1371/journal.pone.0000540.g005
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